Relationship of neurocognition and treatment retention in subjects on opioid agonist treatment

Ghosh, Abhishek; Rana, Devender Kumar; Basu, Debasish; Mattoo, Surendra Kumar; Roub, Fazle; Bammidi, Ravi

doi:10.1080/14659891.2022.2084781

Cited by 1 publication

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In other words, selective retention of those with “relatively preserved” cognitive functions could not account for improved cognitive functions after treatment. A previous study also found that cognitive function at enrollment in an OAMT program did not influence treatment retention at 6 months 38 …”

Section: Discussionmentioning

confidence: 86%

“…A previous study also found that cognitive function at enrollment in an OAMT program did not influence treatment retention at 6 months. 38 Previous studies also showed significant improvements in several cognitive domains following 2 to 6 months of buprenorphine treatment. 21,22 However, both studies showed that patients on treatment still had worse cognitive performance in some domains (eg, working memory, executive functions), which might also impair functioning such as driving abilities and social functioning.…”

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

Neurocognitive Functions After 6-Month Buprenorphine (Naloxone)–Based Opioid Agonist Maintenance Treatment

Ghosh,

Shaktan,

Nehra

et al. 2024

J Clin Psychopharmacol

View full text Add to dashboard Cite

Background Medications for opioid use disorder (OUD) may influence neurocognitive functions. Inadequate power, confounders, and practice effects limit the validity of the existing research. We examined the change in cognitive functions in patients with OUD at 6-month buprenorphine (naloxone) posttreatment and compared the cognitive performance of the buprenorphine-treated group with control subjects. Methods We recruited 498 patients with OUD within a week of initiating buprenorphine. Assessments were done twice—at baseline and 6 months. Those abstinent from illicit opioids and adherent to treatment (n = 199) underwent follow-up assessments. Ninety-eight non–substance-using control subjects were recruited from the community. The neurocognitive assessments comprised the Wisconsin Card Sorting Test, Iowa Gambling Task, Trail-Making Tests A and B (TMT-A and TMT-B), and verbal and visual N-Back Test. We controlled for potential effect modifiers. Results Twenty-five of the 32 test parameters significantly improved with 6 months of buprenorphine treatment; 20 parameters withstood corrections for multiple comparisons (P < 0.001). The improved test domains spread across cognitive tests: Wisconsin Card Sorting Test (perseverative errors and response, categories completed, conceptual responses), TMTs (time to complete), verbal and visual N-Back Tests (hits, omission, and total errors). After treatment, OUD (vs control subjects) had less perseverative response and error (P < 0.001) and higher conceptual response (P = 0.004) and took lesser time to complete TMT-A (P < 0.001) and TMT-B (P = 0.005). The baseline neurocognitive functions did not differ between those who retained and those who discontinued the treatment. Conclusion Cognitive functions improve in patients with OUD on buprenorphine. This improvement is unlikely to be accounted for by the practice effect, selective attrition, and potential confounders.

show abstract

Section: Discussionmentioning

confidence: 86%